Panorama del PD-L2 y correlación con el resultado: un análisis inmunómico

PD-L1 and PD-L2 are inhibitory ligands that interact with PD-1 receptors, enabling immune escape. Though PD-L1 has been extensively studied, much less is known about PD-L2. PD-L2 expression could lead to incomplete blockade of the PD-1 axis by anti-PD-L1 agents and also influence activity of anti-PD-1 agents.

We analyzed PD-L2 transcriptomic expression in a pan-cancer cohort (N=514; 489 patients with advanced/metastatic disease and clinical correlates available) for associations with immunomodulatory variables and outcome.

The most common tumors were colorectal (27% [140/514]), pancreatic (11% [55/514]), and breast cancer (9.5% [49/514]). High PD-L2 expression (≥75^th RNA percentile rank) occurred in 19.5% (100/514) of patients; PD-L2 expression varied across and within tumor types. High PD-L2 independently/significantly correlated with high PD-L1, PD-1, CD4, and TIM-3 RNA levels (both as dichotomized and as linear variables), with high tumor mutational burden (TMB) (≥10 mutations/megabase), and with a breast cancer diagnosis. In 217 patients who received immune checkpoint blockade (mainly anti-PD-1-based regimens), high versus moderate/low PD-L2 predicted longer overall survival (OS) (but not progression-free survival) in univariate analysis (median 1.88 years (95% confidence interval [CI] 1.37-not estimable) versus 1.21 years (95% CI 0.95-1.54) (P = 0.02). In 272 patients who never received immunotherapy, high PD-L2 expression was not prognostic for OS.

High PD-L2 transcripts were more common in breast cancer and associated with high expression of other immune-relevant factors: PD-L1, PD-1, CD4, and TIM-3, and with TMB ≥10 mutations/megabase. High PD-L2 levels correlated with longer OS in immunotherapy-treated patients.

NCT02478931.